Answers are grounded in this paper and cite their sources.
Shows antiplatelet drugs slow diabetic nephropathy progression in diabetic rats, highlighting cilostazol renoprotection.
Background: Platelets have been reported to play a role in the progression and development of diabetic nephropathy (DN). The present study has been designed to investigate the comparative effect of some antiplatelet drugs in streptozotocin (STZ) induced nephropathy in rats. Methods: Diabetic nephropathy was induced by administering single dose of streptozotocin in wistar rats. DN was clinically assessed by estimation of various biochemical parameters and histopathological studies of renal tissue. DN was assessed by measuring serum creatinine, blood urea nitrogen, proteinuria, renal cortical collagen content, lipid profile, serum nitrite/nitrate ratio, renal TBARS, reduced glutathione levels. Results: Administration of these antiplatelet drugs (aspirin, dipyridamole, cilostazol) did not treat the diabetic induced nephropathy, but did retard the progression of the disease to a great extent. Treatment with high dose of cilostazol (25mg/kg, i.p.) shows significant improvement in (BUN, serum creatinine, total urine protein, ratio of kidney wt/body wt, TBARS, reduced glutathione) renal parameters studied for DN. Conclusion: It may be therefore concluded that renoprotective effect of cilostazol is due to its antiplatelet property and through the inhibition of various intracellular pathways.
No takes yet. Share an insight, caveat, or question.
Katyal et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: